HIA
CRSP icon

Harbor Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Harbor Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Sell
2,300
-100
-4% -$5.27K 0.01% 503
2026
Q1 		$114K Hold
2,400
– – 0.01% 490
2025
Q4 		$126K Sell
2,400
-1,200
-33% -$71.9K 0.01% 481
2025
Q3 		$233K Buy
3,600
+650
+22% +$37.3K 0.02% 369
2025
Q2 		$143K Sell
2,950
-805
-21% -$31.2K 0.01% 427
2025
Q1 		$128K Sell
3,755
-700
-16% -$29.7K 0.01% 427
2024
Q4 		$175K Sell
4,455
-1,350
-23% -$63.7K 0.02% 373
2024
Q3 		$273K Sell
5,805
-20
-0.3% -$1.01K 0.03% 304
2024
Q2 		$315K Sell
5,825
-345
-6% -$20K 0.03% 276
2024
Q1 		$421K Hold
6,170
– – 0.04% 247
2023
Q4 		$386K Sell
6,170
-450
-7% -$24.9K 0.04% 241
2023
Q3 		$300K Sell
6,620
-4
-0.1% -$207 0.04% 259
2023
Q2 		$372K Sell
6,624
-550
-8% -$31.2K 0.05% 259
2023
Q1 		$324K Sell
7,174
-700
-9% -$34K 0.05% 276
2022
Q4 		$320K Sell
7,874
-3,250
-29% -$172K 0.05% 269
2022
Q3 		$727K Sell
11,124
-200
-2% -$14.5K 0.12% 153
2022
Q2 		$688K Sell
11,324
-50
-0.4% -$2.94K 0.11% 165
2022
Q1 		$714K Sell
11,374
-4,170
-27% -$262K 0.09% 178
2021
Q4 		$1.18M Sell
15,544
-530
-3% -$46.3K 0.15% 122
2021
Q3 		$1.8M Sell
16,074
-320
-2% -$40.2K 0.24% 79
2021
Q2 		$2.65M Buy
16,394
+350
+2% +$42.6K 0.36% 58
2021
Q1 		$1.96M Buy
16,044
+676
+4% +$102K 0.29% 71
2020
Q4 		$2.35M Buy
15,368
+3,120
+25% +$369K 0.38% 60
2020
Q3 		$1.02M Sell
12,248
-1,711
-12% -$152K 0.2% 99
2020
Q2 		$1.03M Buy
13,959
+3,656
+35% +$214K 0.22% 90
2020
Q1 		$437K Buy
10,303
+804
+8% +$41.5K 0.12% 142
2019
Q4 		$579K Buy
+9,499
New +$519K 0.13% 141

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Harbor Investment Advisory's CRSP Position: Q2 2026 in Review

Harbor Investment Advisory reduced its CRISPR Therapeutics (CRSP) stake by 4.2% in Q2 2026, selling an estimated $5.27K and leaving 2,300 shares worth $125K. The position accounts for 0.01% of the portfolio, ranked #503.

Harbor Investment Advisory first reported a position in CRSP in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.65M in Q2 2021. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Harbor Investment Advisory held 2,300 shares of CRISPR Therapeutics worth $125K as of Q2 2026.
  • Harbor Investment Advisory sold 100 CRISPR Therapeutics shares in Q2 2026, an estimated $5.27K.
  • CRISPR Therapeutics made up 0.01% of Harbor Investment Advisory's portfolio in Q2 2026, its #503 holding.
  • Harbor Investment Advisory first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Harbor Investment Advisory's CRISPR Therapeutics position peaked at $2.65M in Q2 2021.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Harbor Investment Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.